Compare Stocks: UPB, IMTX, MNKD, and MLTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$8.79 +0.5%	$9.34	$5.67 ▼ $12.41	$1.20B	1.33	651,536 shs	527,248 shs
MLTX MoonLake Immunotherapeutics	$12.51 -5.1%	$17.26	$5.95 ▼ $62.75	$1.06B	1.04	1.07 million shs	2.38 million shs
MNKD MannKind	$3.75 -1.1%	$4.01	$2.23 ▼ $6.51	$1.21B	1.1	3.04 million shs	2.47 million shs
UPB Upstream Bio	$5.73 -0.3%	$6.81	$5.65 ▼ $33.68	$313.84M	1.28	601,672 shs	501,307 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	0.00%	-8.05%	-8.34%	-6.29%	+51.29%
MLTX MoonLake Immunotherapeutics	0.00%	-16.66%	-24.18%	-33.07%	-76.92%
MNKD MannKind	0.00%	-7.64%	+0.54%	+2.46%	-32.68%
UPB Upstream Bio	0.00%	-4.66%	-17.08%	-6.07%	-67.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$8.79 +0.5%	$9.34	$5.67 ▼ $12.41	$1.20B	1.33	651,536 shs	527,248 shs
MLTX MoonLake Immunotherapeutics	$12.51 -5.1%	$17.26	$5.95 ▼ $62.75	$1.06B	1.04	1.07 million shs	2.38 million shs
MNKD MannKind	$3.75 -1.1%	$4.01	$2.23 ▼ $6.51	$1.21B	1.1	3.04 million shs	2.47 million shs
UPB Upstream Bio	$5.73 -0.3%	$6.81	$5.65 ▼ $33.68	$313.84M	1.28	601,672 shs	501,307 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	0.00%	-8.05%	-8.34%	-6.29%	+51.29%
MLTX MoonLake Immunotherapeutics	0.00%	-16.66%	-24.18%	-33.07%	-76.92%
MNKD MannKind	0.00%	-7.64%	+0.54%	+2.46%	-32.68%
UPB Upstream Bio	0.00%	-4.66%	-17.08%	-6.07%	-67.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	2.63	Moderate Buy	$20.60	134.36% Upside
MLTX MoonLake Immunotherapeutics	2.41	Hold	$24.57	96.41% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	122.50% Upside
UPB Upstream Bio	2.43	Hold	$29.67	417.74% Upside

Current Analyst Ratings Breakdown

Latest UPB, IMTX, MNKD, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/7/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$14.00 ➝ $13.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$54.60M	22.01	N/A	N/A	$4.09 per share	2.15
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
MNKD MannKind	$393.63M	3.06	$0.06 per share	60.60	($0.17) per share	-22.06
UPB Upstream Bio	$2.85M	110.12	N/A	N/A	$6.29 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest UPB, IMTX, MNKD, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	7.54	7.54
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
MNKD MannKind	N/A	1.72	1.41
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
MLTX MoonLake Immunotherapeutics	93.85%
MNKD MannKind	49.55%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
MLTX MoonLake Immunotherapeutics	10.40%
MNKD MannKind	2.60%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	704	136.69 million	132.18 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable
UPB Upstream Bio	38	54.77 million	45.76 million	N/A

UPB, IMTX, MNKD, and MLTX Headlines

Recent News About These Companies

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

HC Wainwright Forecasts Reduced Earnings for Upstream Bio

September 6, 2026 | americanbankingnews.com

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4, 2026 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Upstream Bio (NASDAQ:UPB)

September 4, 2026 | americanbankingnews.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3, 2026 | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2, 2026 | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

August 14, 2026 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

August 14, 2026 | marketbeat.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, IMTX, MNKD, and MLTX Company Descriptions

Immatics NASDAQ:IMTX

$8.79 +0.04 (+0.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.80 +0.01 (+0.11%)

As of 09/11/2026 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

MoonLake Immunotherapeutics NASDAQ:MLTX

$12.51 -0.67 (-5.08%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.62 +0.11 (+0.84%)

As of 09/11/2026 07:51 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MannKind NASDAQ:MNKD

$3.75 -0.04 (-1.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.77 +0.02 (+0.43%)

As of 09/11/2026 07:59 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Upstream Bio NASDAQ:UPB

$5.73 -0.02 (-0.35%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.72 -0.01 (-0.09%)

As of 09/11/2026 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPB, IMTX, MNKD, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPB, IMTX, MNKD, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPB, IMTX, MNKD, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, IMTX, MNKD, and MLTX Company Descriptions

Immatics NASDAQ:IMTX

MoonLake Immunotherapeutics NASDAQ:MLTX

MannKind NASDAQ:MNKD

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPB, IMTX, MNKD, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPB, IMTX, MNKD, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPB, IMTX, MNKD, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, IMTX, MNKD, and MLTX Company Descriptions

Immatics NASDAQ:IMTX

MoonLake Immunotherapeutics NASDAQ:MLTX

MannKind NASDAQ:MNKD

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools